Ken Griffin Werewolf Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,600 shares of HOWL stock, worth $3,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,600
Previous 2,400
33.33%
Holding current value
$3,247
Previous $15,000
80.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding HOWL
# of Institutions
73Shares Held
32.2MCall Options Held
53.8KPut Options Held
1.3K-
Ra Capital Management, L.P. Boston, MA6.14MShares$12.5 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$8.7 Million5.74% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.24MShares$6.58 Million0.41% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$4.85 Million0.94% of portfolio
-
Bank Of America Corp Charlotte, NC2.15MShares$4.36 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $59.9M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...